Interscalene Single Shot With Plain Bupivacaine Versus Liposomal Bupivacaine for Arthroscopic Shoulder Surgery
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The investigators will be comparing pain scores and opioid use in patients receiving
interscalene peripheral blocks with plain bupivacaine versus those receiving liposomal
bupivacaine. Liposomal bupivacaine is described as releasing local anesthetic up to 72 hours
after its injection; therefore if liposomal bupivacaine can provide extended pain relief
compared to plain bupivacaine, the investigators can consider using it as our primary local
anesthetic. As secondary outcomes, the investigators will also be looking at difference in
functional status and long-term differences between the two local anesthetics.